INNOVENT BIO (1801.HK)

HKSE - HKSE Delayed Price. Currency in HKD

35.050

-0.450

(-1.27%)

At close: 04:08PM HKT

Loading interactive chart...

PR Newswire
Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces the latest clinical results of a multicenter, open-label Phase 2 study (ClinicalTrials.gov, NCT05970978) of picankibart (R&D code: IBI112), a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection
Clinical Trials Arena
Innovent’s trial of picankibart for ulcerative colitis meets primary endpoint
The primary endpoint was clinical remission at week 12, with secondary endpoints of clinical response and endoscopic remission.